Wong-type dermatomyositis during anti–PD-1 therapy

Abstract

Checkpoint inhibitors used for cancer immunotherapy may also result in autoimmunity.1,2 We present a case of Wong-type dermatomyositis complicating treatment with nivolumab, an inhibitor of the programmed cell death 1 (PD-1) receptor. Wong-type dermatomyositis is a rare variant of classic dermatomyositis with concurrent clinical and histopathologic findings mimicking pityriasis rubra pilaris.3 Our report of nivolumab-related Wong-type dermatomyositis expands the clinical spectrum of autoimmune diseases associated with checkpoint inhibitors.